News & Events
For media inquiries email [email protected]
Company news
May 30, 2025
Press Release
Parabilis Medicines to Present Overview of Ongoing Phase 1/2 Study of FOG-001, a β-cateninTCF4 Inhibitor, at Upcoming Medical Meetings
April 25, 2025
Press Release
Parabilis Medicines Reports Positive Proof-of-Mechanism Data for Groundbreaking ERG Degrader Program
April 23, 2025
Press Release
Parabilis Medicines to Present First Preclinical Data on ERG Degrader Program at AACR Annual Meeting
Publications and presentations
June 2, 2025
ASCO Annual Meeting
A Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer (CRC) and other locally advanced or metastatic solid tumors
May 2, 2025
AACR Annual Meeting
Degradation of the ETS transcription factor ERG by stabilized helical peptide (Helicon) degraders enables pharmacological validation in ERG-fusion prostate cancer models
March 5, 2024
Nature Communications
Mirror-image ligand discovery enabled by single-shot fast-flow synthesis of D-proteins
Recent highlights
May 2, 2025
Podcast
“Therapeutic Momentum” Interview with Mathai Mammen
Parabilis CEO Mathai Mammen joined Karen Akinsanya, head of therapeutics R&D at Schrodinger, on the Therapeutic Momentum podcast for a wide-ranging discussion of science, leadership, purpose — and the very human motivations that fuel innovation.